F. Rosenkaimer
About
In The Last Decade
F. Rosenkaimer
20 papers receiving 847 citations
Peers
Comparison fields: 5 of 64
- Public Health, Environmental and Occupational Health 478
- Epidemiology 323
- Oncology 208
- Immunology 163
- Molecular Biology 160
Countries citing papers authored by F. Rosenkaimer
This map shows the geographic impact of F. Rosenkaimer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Rosenkaimer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Rosenkaimer more than expected).
Fields of papers citing papers by F. Rosenkaimer
This network shows the impact of papers produced by F. Rosenkaimer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Rosenkaimer. The network helps show where F. Rosenkaimer may publish in the future.
Co-authorship network of co-authors of F. Rosenkaimer
This figure shows the co-authorship network connecting the top 25 collaborators of F. Rosenkaimer. A scholar is included among the top collaborators of F. Rosenkaimer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. Rosenkaimer. F. Rosenkaimer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 10 | |
| 2 | 112 | |
| 3 | 33 | |
| 4 | 192 | |
| 5 | 64 | |
| 6 | Administration of high-dose tumor necrosis factor alpha by isolation perfusion of the limbs. Rationale and results. | 20 |
| 7 | [Efficacy of the tumor necrosis factor-alpha (rTNF-alpha) associated with interferon-gamma and chemotherapy in extracorporeal circulation in the limb in inoperable malignant melanoma, soft tissue sarcoma and epidermoid carcinoma. A 4-year experience]. | 3 |
| 8 | 44 | |
| 9 | 71 | |
| 10 | Clinical experience with high-dose tumor necrosis factor alpha in regional therapy of advanced melanoma. | 37 |
| 11 | 44 | |
| 12 | Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study. | 84 |
| 13 | 15 | |
| 14 | 57 | |
| 15 | Clinical experiences with interferon-alpha and interferon-gamma. | 9 |
| 16 | 7 | |
| 17 | 9 | |
| 18 | 39 | |
| 19 | Topical alpha interferon in the treatment of oral ulcers in Behçet's syndrome: a preliminary report. | 18 |
| 20 | Inhibition of Plasmodium vinckei-malaria in mice by recombinant murine interferon-gamma. | 16 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.